Cargando…
The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745994/ https://www.ncbi.nlm.nih.gov/pubmed/31723777 http://dx.doi.org/10.1097/HS9.0000000000000052 |
| _version_ | 1783451634987171840 |
|---|---|
| author | Borchmann, Peter Fosså, Alexander Długosz-Danecka, Monika Böll, Boris Dietlein, Markus Kobe, Carsten Goergen, Helen Engert, Andreas |
| author_facet | Borchmann, Peter Fosså, Alexander Długosz-Danecka, Monika Böll, Boris Dietlein, Markus Kobe, Carsten Goergen, Helen Engert, Andreas |
| author_sort | Borchmann, Peter |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6745994 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Wolters Kluwer Health |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-67459942019-11-13 The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered Borchmann, Peter Fosså, Alexander Długosz-Danecka, Monika Böll, Boris Dietlein, Markus Kobe, Carsten Goergen, Helen Engert, Andreas Hemasphere Editorial Wolters Kluwer Health 2018-06-11 /pmc/articles/PMC6745994/ /pubmed/31723777 http://dx.doi.org/10.1097/HS9.0000000000000052 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. http://creativecommons.org/licenses/by-sa/4.0 This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-sa/4.0 |
| spellingShingle | Editorial Borchmann, Peter Fosså, Alexander Długosz-Danecka, Monika Böll, Boris Dietlein, Markus Kobe, Carsten Goergen, Helen Engert, Andreas The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered |
| title | The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered |
| title_full | The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered |
| title_fullStr | The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered |
| title_full_unstemmed | The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered |
| title_short | The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered |
| title_sort | phase 3 study echelon-1 evaluating brentuximab vedotin in patients with newly diagnosed hodgkin lymphoma leaves important questions unanswered |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745994/ https://www.ncbi.nlm.nih.gov/pubmed/31723777 http://dx.doi.org/10.1097/HS9.0000000000000052 |
| work_keys_str_mv | AT borchmannpeter thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT fossaalexander thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT długoszdaneckamonika thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT bollboris thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT dietleinmarkus thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT kobecarsten thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT goergenhelen thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT engertandreas thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT borchmannpeter phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT fossaalexander phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT długoszdaneckamonika phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT bollboris phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT dietleinmarkus phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT kobecarsten phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT goergenhelen phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered AT engertandreas phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered |